VAI TRÒ CỦA XẠ HÌNH XƯƠNG TRONG ĐÁNH GIÁ GIAI ĐOẠN UNG THƯ TUYẾN TIỀN LIỆT TẠI KHOA XẠ TRỊ, BỆNH VIỆN E

Abstract

Study Objective: To evaluate the role of bone scintigraphy in staging prostate cancer (PCa) at E Hospital, determine the rate of patients with bone metastasis detected by BS, and analyze the relationship between BS results and the risk factors PSA and Gleason score of the tumor. Subjects: The study included 253 male patients diagnosed with PCa who underwent bone scintigraphy at E Hospital. Inclusion criteria: (1) Pathological confirmation of prostate cancer; (2) Staging evaluation before treatment using whole-body bone scintigraphy. Exclusion criteria: Patients who refused to participate in the study. Patients were enrolled between 02/2023 and 05/2025 at the Radiation Oncology Department, E Hospital. This is a cross-sectional, retrospective, and prospective study based on medical records and bone scintigraphy results. Method: All patients received intravenous injection of Technetium-99m MDP and underwent whole-body bone scintigraphy using a two-head gamma camera system (SPECT Intevo, Siemens). The BS images were interpreted by a nuclear medicine specialist. The criteria for detecting bone metastasis on BS were abnormal focal uptake of radioactivity localized in the bones, with asymmetric bilateral involvement, excluding areas of increased uptake due to trauma or osteoarthritis. The BS results were cross-checked with clinical data and other diagnostic tests (such as PSA levels, CT or MRI scans if available) to increase diagnostic accuracy. Data on age, initial PSA levels, and Gleason score from biopsy were collected. We classified patients by age, PSA level (< 20 ng/mL or ≥ 20 ng/mL), and Gleason score (< 8 or ≥ 8) to assess the rate of bone metastasis in each group. The data were processed and analyzed using descriptive statistics with SPSS 22.0.